Long-term human response following subretinal injection of recombinant adenoassociated virus-sFlt-1 vector

点击翻译按钮获取中文摘要

Age-related Macular Degeneration (AMD) is the major cause of blindness in the developed world. The present best practice for treating wet AMD is monthly injections of Lucentis� into the eye which is expensive, inconvenient for the patient and has increased risk of infection. The additional assays associated with the clinical trial will test whether adeno-associated virus-mediated gene therapy is safe and whether it can eliminate the need of multiple injections while delivering the same outcome.